๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Protein binding and erythrocyte partitioning of disopyramide and its monodealkylated metabolite

โœ Scribed by Peter H. Hinderling; Janine Bres; Edward R. Garrett

Publisher
John Wiley and Sons
Year
1974
Tongue
English
Weight
865 KB
Volume
63
Category
Article
ISSN
0022-3549

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Influence of concentration-dependent pro
Influence of concentration-dependent protein binding on serum concentrations and urinary excretion of disopyramide and its metabolite following oral administration
โœ David B. Haughey; John J. Lima ๐Ÿ“‚ Article ๐Ÿ“… 1983 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 494 KB ๐Ÿ‘ 1 views

## Abstract Concentrations of disopyramide (D) and monoโ€Nโ€dealkyldisopyramide (MND) were measured in serum and urine following administration of 100, 150, 200, and 300 mg D to four volunteers. The free fraction of D in serum was drug concentrationโ€dependent in all four subjects following the admini

Human serum and plasma protein binding o
Human serum and plasma protein binding of enoximone and its sulfoxide metabolite
โœ Robert H. Hook; Harold Boxenbaum; Gary A. Thompson; Richard A. Okerholm ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 752 KB

Experimental factors and determinants of the protein binding of enoximone (a new cardiotonic agent) were investigated in human serum from healthy, drug-free subjects using a rapid ultrafiltration method; these factors and determinants included nonspecific binding to the apparatus, ultrafiltrate volu

Comparative class 1 electrophysiologic a
Comparative class 1 electrophysiologic and anticholinergic effects of disopyramide and its main metabolite (mono-N-dealkylated disopyramide) in healthy humans
โœ Lennart Bergfeldt; Karin Schenck-Gustafsson; Rune Dahlqvist ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› Springer US ๐ŸŒ English โš– 860 KB

During steady-state treatment with disopyramide, its main and active metabolite, mono-N-dealkylated disopyramide, was reported to reach concentrations that were equal to or higher than the parent drug in 25% of 70 evaluated patients. This metabolite has been found to have a more pronounced anticholi